Veracyte, Inc.
VCYT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $131,872 | $130,164 | $114,473 | $118,632 |
| % Growth | 1.3% | 13.7% | -3.5% | – |
| Cost of Goods Sold | $42,517 | $40,395 | $34,965 | $39,878 |
| Gross Profit | $89,355 | $89,769 | $79,508 | $78,754 |
| % Margin | 67.8% | 69% | 69.5% | 66.4% |
| R&D Expenses | $15,537 | $16,264 | $17,720 | $19,290 |
| G&A Expenses | $0 | $13,797 | $52,342 | $47,128 |
| SG&A Expenses | $50,706 | $56,748 | $59,161 | $54,807 |
| Sales & Mktg Exp. | $0 | $42,951 | $6,819 | $7,679 |
| Other Operating Expenses | $0 | $22,025 | -$277 | $482 |
| Operating Expenses | $66,243 | $95,037 | $76,604 | $74,579 |
| Operating Income | $23,112 | -$5,268 | $2,904 | $4,175 |
| % Margin | 17.5% | -4% | 2.5% | 3.5% |
| Other Income/Exp. Net | -$4,223 | $6,518 | $4,524 | -$732 |
| Pre-Tax Income | $18,889 | $1,250 | $7,428 | $3,443 |
| Tax Expense | -$248 | $2,230 | $381 | -$1,670 |
| Net Income | $19,137 | -$980 | $7,047 | $5,113 |
| % Margin | 14.5% | -0.8% | 6.2% | 4.3% |
| EPS | 0.243 | -0.013 | 0.09 | 0.07 |
| % Growth | 2,044.8% | -113.9% | 28.6% | – |
| EPS Diluted | 0.24 | -0.013 | 0.088 | 0.06 |
| Weighted Avg Shares Out | 78,725 | 78,211 | 78,028 | 77,609 |
| Weighted Avg Shares Out Dil | 79,692 | 79,905 | 80,056 | 79,905 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,482 | $2,937 | $2,762 | $2,861 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5,266 | $5,489 | $5,362 | $6,253 |
| EBITDA | $24,155 | $6,739 | $6,526 | $9,696 |
| % Margin | 18.3% | 5.2% | 5.7% | 8.2% |